CRSPCRISPR Therapeutics AG

Nasdaq crisprtx.com


$ 53.27 $ -2.24 (-4.03 %)    

Wednesday, 08-May-2024 15:59:56 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 53.29
$ 53.53
$ 53.32 x 100
$ 0.00 x 0
$ 52.64 - $ 54.50
$ 37.55 - $ 91.10
1,522,876
na
4.36B
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-08-2023 03-31-2023 10-Q
6 02-21-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-15-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 04-27-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-27-2020 06-30-2020 10-Q
17 04-28-2020 03-31-2020 10-Q
18 02-12-2020 12-31-2019 10-K
19 10-28-2019 09-30-2019 10-Q
20 07-29-2019 06-30-2019 10-Q
21 04-29-2019 03-31-2019 10-Q
22 02-25-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-08-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-11-2017 03-31-2017 10-Q
30 03-10-2017 12-31-2016 10-K
31 11-22-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-neutral-on-crispr-therapeutics-raises-price-target-to-52

Baird analyst Jack Allen maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and raises the price target from $46 to...

 crispr-therapeutics-q1-eps-143-misses-142-estimate-sales-50400k-miss-2811m-estimate

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of...

 citigroup-maintains-buy-on-crispr-therapeutics-raises-price-target-to-89

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from ...

 needham-reiterates-buy-on-crispr-therapeutics-maintains-90-price-target

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $90 price target.

 cathie-woods-ark-invest-keeps-dumping-coinbase-shares-amid-bitcoin-crypto-buzz

On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global ...

 mizuho-maintains-buy-on-crispr-therapeutics-raises-price-target-to-99

Mizuho analyst Salim Syed maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $99.

 median-drug-prices-for-rare-diseases-hit-300k-in-2023-report-highlights-lack-of-clear-rationale-behind-escalating-drug-prices

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on r...

 morgan-stanley-maintains-underweight-on-crispr-therapeutics-raises-price-target-to-48

Morgan Stanley analyst Terence Flynn maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Underweight and raises the price tar...

 rbc-capital-maintains-sector-perform-on-crispr-therapeutics-raises-price-target-to-66

RBC Capital analyst Luca Issi maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Sector Perform and raises the price target ...

 analog-devices-to-rally-around-19-here-are-10-top-analyst-forecasts-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 chardan-capital-maintains-buy-on-crispr-therapeutics-raises-price-target-to-112

Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target f...

 needham-maintains-buy-on-crispr-therapeutics-raises-price-target-to-90

Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.

 whats-going-on-with-crispr-therapeutics-stock

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Ther...

 reliance-steel--aluminum-posts-upbeat-earnings-joins-jfrog-applovin-shake-shack-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

 wolfe-research-initiates-coverage-on-crispr-therapeutics-with-peer-perform-rating

Wolfe Research analyst Andy Chen initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Peer Perform rating.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION